Gilead Sciences GILD
NASDAQ GILD
$144.80 -0.85 (-0.58%)
As of: Sep 10, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Work In Process (2009 - 2015)

Gilead Sciences' (GILD) quarterly Work In Process came in at $542.0 million in Q4 2015, up 8.4% on a YoY basis from $500.0 million in Q4 2014, and up 8.4% quarter-over-quarter from $500.0 million in Q4 2014.

Analysis

Gilead Sciences (GILD) Work In Process (2009 - 2015) Analysis & Trends

Gilead Sciences (GILD) has reported Work In Process for 7 consecutive years, with $542.0 million the latest figure, recorded in Q4 2015.

  • For the quarter ending Q4 2015, Work In Process rose 8.4% year-over-year to $542.0 million; the trailing twelve-month figure through Dec 2015 stood at $542.0 million (up 8.4% YoY), and the FY2015 full-year result was $542.0 million, up 8.4% from the prior year.
  • Work In Process advanced to $542.0 million in Q4 2015 per GILD's latest filing, from $500.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $563.9 million in Q2 2014 and bottomed at $175.5 million in Q3 2011.
  • Historically, Work In Process has averaged $398.7 million across 5 years, with a median of $412.9 million in 2013.
  • The sharpest annual moves came in 2011 and 2014: Work In Process sank 55.28% in 2011, then advanced 21.08% in 2014.
  • Over 5 years, Work In Process stood at $466.5 million in 2011, then retreated by 23.15% to $358.5 million in 2012, then increased by 15.18% to $412.9 million in 2013, then rose by 21.08% to $500.0 million in 2014, then rose by 8.4% to $542.0 million in 2015.
  • According to Business Quant data, Work In Process over the past three periods registered $542.0 million, $500.0 million, and $563.9 million for Q4 2015, Q4 2014, and Q2 2014 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Insmed 27.67 Bn 26.51 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 542.00 Mn
Dec 31, 2014 500.00 Mn
Jun 30, 2014 563.88 Mn
Dec 31, 2013 412.95 Mn
Dec 31, 2012 358.53 Mn
Dec 31, 2011 466.50 Mn
Sep 30, 2011 175.55 Mn
Jun 30, 2011 271.64 Mn
Mar 31, 2011 296.87 Mn
Dec 31, 2010 454.65 Mn
Sep 30, 2010 392.54 Mn
Dec 31, 2009 392.04 Mn